N-Nonyldeoxynojirimycin Composition for Dual-Pathway Skin Itching

Resolve Bottlenecks,
Find Innovative SolutionsGenerate Solutions

Solution Overview

Problem

Existing treatments for skin itching, particularly those related to the skin barrier and abnormal immune responses, are inadequate in effectively inhibiting or alleviating the symptoms.

Innovation Solution

A pharmaceutical and cosmetic composition containing N-nonyldeoxynojirimycin (NN-DNJ) that inhibits the release of β-hexosaminidase and prostaglandin 2 (PGE2) in mast cells, thereby addressing both types of skin itching.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Adaptability or versatility

If conventional topical cosmetic materials are used, then skin itching associated with skin barrier may be addressed, but skin itching associated with abnormal immune responses cannot be effectively treated

Engineering Contradiction:

Improvetreatment coverageVSAvoidtreatment effectiveness

Core Design Contradiction:

Adaptability or versatilityVSReliability

Solution Approach 1:

The patent applies universality by using N-nonyldeoxynojirimycin as a single active ingredient that performs multiple functions: it inhibits beta-hexosaminidase release in mast cells (addressing immune response itching) while also being suitable for topical application (addressing skin barrier itching). This multi-functional approach allows one composition to treat both types of skin itching that previously required different treatment strategies.

Inventive Principle:

Principle #6Universality (Multi-functionality)

2Reliability

If N-nonyldeoxynojirimycin is used to inhibit both skin itching types, then treatment effectiveness is improved, but composition complexity increases

Engineering Contradiction:

Improvetreatment effectivenessVSAvoidcomposition complexity

Core Design Contradiction:

ReliabilityVSDevice complexity

Solution Approach 1:

The patent applies parameter changes by optimizing the concentration of N-nonyldeoxynojirimycin in the composition (0.01-10% by weight) to achieve effective inhibition of both skin itching types while maintaining formulation simplicity. The specific concentration range was determined to balance therapeutic effectiveness with formulation stability and ease of manufacture.

Inventive Principle:

Principle #35Parameter changes

3Productivity

If existing treatments are used for skin barrier itching, then mild symptoms are addressed, but chronic and severe itching cases are not effectively resolved

Engineering Contradiction:

Improvesymptom resolution rateVSAvoidapplicability to chronic cases

Core Design Contradiction:

ProductivityVSAdaptability or versatility

Solution Approach 1:

The patent applies preliminary action by using N-nonyldeoxynojirimycin to prevent the release of beta-hexosaminidase and other inflammatory mediators from mast cells before they can cause severe itching symptoms. This preventive mechanism addresses both mild and chronic itching by blocking the inflammatory cascade at an early stage, thereby improving outcomes for chronic and severe cases.

Inventive Principle:

Principle #10Preliminary action

Data Source

PatentEP4609862A1Composition containing n-nonyldeoxynojirimycin for suppression, alleviation, palliation, or treatment of skin itching

Publication Date: 2025.09.03 COLLEGE OF MEDICINE POCHON CHA UNIV IND ACADEMIC COOP FOUND

Figure 1
Figure 2
Figure 3

AI summary

The present invention provides a pharmaceutical composition for the inhibition, alleviation, or treatment of skin itching; and a cosmetic composition for the inhibition, alleviation, or improvement of skin itching, comprising N-nonyldeoxynojirimycin.